p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

BACKGROUND: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Exp Clin Cancer Res
Main Authors: Giordano, Federica, Vaira, Valentina, Cortinovis, Diego, Bonomo, Sara, Goedmakers, Joyce, Brena, Federica, Cialdella, Annamaria, Ianzano, Leonarda, Forno, Irene, Cerrito, Maria Grazia, Giovannoni, Roberto, Ferri, Gian Luca, Tasciotti, Ennio, Vicent, Silve, Damarco, Francesco, Bosari, Silvano, Lavitrano, Marialuisa, Grassilli, Emanuela
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6570906/
https://ncbi.nlm.nih.gov/pubmed/31200752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1199-7
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים